Trial Profile
A multi-centre trial of eculizumab evaluating time to haematologic and renal improvements in patients aged 12 years and above with atypical haemolytic uraemic syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2014
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- 25 Apr 2014 New trial record